108 related articles for article (PubMed ID: 23892825)
1. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Sep; 934():22-5. PubMed ID: 23892825
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():626-9. PubMed ID: 24216281
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2014 Jan; 88():216-20. PubMed ID: 24080524
[TBL] [Abstract][Full Text] [Related]
5. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
[TBL] [Abstract][Full Text] [Related]
7. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
9. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetic profiles of selected irreversible tyrosine kinase inhibitors, neratinib and pelitinib, with apigenin in rat plasma by UPLC-MS/MS.
Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
J Pharm Biomed Anal; 2017 Apr; 137():258-267. PubMed ID: 28167419
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():169-73. PubMed ID: 22476055
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
Sparidans RW; Martens I; Valkenburg-van Iersel LB; den Hartigh J; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1851-6. PubMed ID: 21622034
[TBL] [Abstract][Full Text] [Related]
15. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
[TBL] [Abstract][Full Text] [Related]
16. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
[TBL] [Abstract][Full Text] [Related]
18. Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study.
Lou Y; Hu H; Liu Y; Yu Q; Li L; Ping L; Yu L; Jiang H; Zeng S
J Pharm Biomed Anal; 2011 Jul; 55(5):1163-9. PubMed ID: 21549539
[TBL] [Abstract][Full Text] [Related]
19. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats.
Li B; Wang J; Dou X; Zhang X; Xue X; Xu Q; Ran W; Xiong S
Comb Chem High Throughput Screen; 2021; 24(9):1410-1416. PubMed ID: 33155888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
